Johnson Chemical Pharmaceutical Works Co (ROCO:4747) Other Stockholders Equity: NT$128.2 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4747 Johnson Chemical Pharmaceutical Works Co ROCO:4747
77 GF Score
Price NT$49.80
GF Value NT$60.09
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Johnson Chemical Pharmaceutical Works Co Other Stockholders Equity?

Johnson Chemical Pharmaceutical Works Co ROCO:4747 +0.81% 77 Other Stockholders Equity is NT$128.2 Mil as of Dec. 2025. GuruFocus rates ROCO:4747 with a GF Score™ of 77/100 and a GF Value™ of NT$60.09 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Johnson Chemical Pharmaceutical Works Co's Other Stockholders Equity for the quarter that ended in Dec. 2025 was NT$128.2 Mil.

Johnson Chemical Pharmaceutical Works Co's quarterly Other Stockholders Equity declined from Jun. 2025 (NT$127.1 Mil) to Sep. 2025 (NT$126.8 Mil) but then increased from Sep. 2025 (NT$126.8 Mil) to Dec. 2025 (NT$128.2 Mil).

Johnson Chemical Pharmaceutical Works Co's annual Other Stockholders Equity increased from Dec. 2023 (NT$110.5 Mil) to Dec. 2024 (NT$115.9 Mil) and increased from Dec. 2024 (NT$115.9 Mil) to Dec. 2025 (NT$128.2 Mil).

Johnson Chemical Pharmaceutical Works Co Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Johnson Chemical Pharmaceutical Works Co's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Johnson Chemical Pharmaceutical Works Co Other Stockholders Equity Chart

Johnson Chemical Pharmaceutical Works Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 99.30 103.35 110.46 115.87 128.22

Johnson Chemical Pharmaceutical Works Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 115.87 117.34 127.12 126.79 128.22
ROCO:4747
77GF Score
Johnson Chemical Pharmaceutical Works Co ROCO:4747
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Johnson Chemical Pharmaceutical Works Co Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of NT$128.2 Mil mean?
Johnson Chemical Pharmaceutical Works Co (ROCO:4747) has a Other Stockholders Equity of NT$128.2 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Johnson Chemical Pharmaceutical Works Co and its competitors.
Is Johnson Chemical Pharmaceutical Works Co's Other Stockholders Equity too high?
Johnson Chemical Pharmaceutical Works Co's current Other Stockholders Equity is NT$128.2 Mil. Overall, Johnson Chemical Pharmaceutical Works Co has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Johnson Chemical Pharmaceutical Works Co's Other Stockholders Equity compare to ZTS?
Johnson Chemical Pharmaceutical Works Co's Other Stockholders Equity of NT$128.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Johnson Chemical Pharmaceutical Works Co and its competitors. Johnson Chemical Pharmaceutical Works Co's current Other Stockholders Equity is NT$128.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Johnson Chemical Pharmaceutical Works Co stock overvalued right now?
Based on GuruFocus' analysis, Johnson Chemical Pharmaceutical Works Co (ROCO:4747) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$60.09, compared to a current price of NT$49.80 — trading 17.1% below its estimated fair value. The current Other Stockholders Equity is NT$128.2 Mil. Johnson Chemical Pharmaceutical Works Co's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Johnson Chemical Pharmaceutical Works Co (ROCO:4747), the current Other Stockholders Equity is NT$128.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Johnson Chemical Pharmaceutical Works Co (ROCO:4747) Overvalued in 2026?

Based on GuruFocus' analysis, Johnson Chemical Pharmaceutical Works Co stock appears to be undervalued. The current stock price of NT$49.80 is trading 17.1% below its estimated GF Value™ of NT$60.09. GuruFocus considers Johnson Chemical Pharmaceutical Works Co to be Modestly Undervalued.

Key valuation signals for ROCO:4747:

  • Other Stockholders Equity: NT$128.2 Mil
  • GF Value™: NT$60.09 vs. price of NT$49.80 (17.1% below fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the ROCO:4747 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Johnson Chemical Pharmaceutical Works Co Business Description

Address Sanhe Road, No. 77 and No. 79, Section 4, Sanchong District, New Taipei City, TWN, 241
Johnson Chemical Pharmaceutical Works Co is engaged in the manufacturing of pharmaceutical ingredients, importing and selling pharmaceutical materials and products. It manufactures drugs in a variety of forms, including solid dosage forms, capsules (soft/hard), tablets (sugar/film-coated), powder and granule, as well as nasal sprays. It offers products in therapeutic areas including the central nervous system, respiratory, cardiovascular, gastrointestinal, and endocrine system, vitamins, anti-inflammatory, cough and cold, and pain relievers. Its revenue mainly comes from medical product sales.
77GF Score

Get the complete analysis for ROCO:4747

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$49.80
Price
NT$60.09
GF Value